Featuring perspectives from Dr Benjamin Levy, including the following topics:

• Introduction: The Boards (0:00)
• Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43)
• Immunotherapy for Metastatic NSCLC (24:41)
• Antibody-Drug Conjugates (33:46)
• Novel Bispecific Antibodies (42:08)
• Journal Club with Dr Levy (51:28)

CME information and select publications

Featuring perspectives from Prof Xavier Leleu and Dr Peter Voorhees, including the following topics:

• Introduction: Myeloma Time Capsule (0:00)
• Smoldering Myeloma (7:21)
• Autologous Stem Cell Transplant (ASCT) Eligible Patients (13:05)
• ASCT Ineligible Patients (32:18)
• Subcutaneous Anti-CD38 Antibodies (47:24)
• Special Considerations (54:27)

CME information and select publications

Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma | Faculty Presentation — Peter Voorhees, MD

CME information and select publications

Featuring an interview with Dr Erika Hamilton, including the following topics:

• Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00)
  • Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract 
  • Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025;Abstract VP1-2025.
• First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02)
  • Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025;Abstract LBA109.
• Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06)
  • Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract
  • McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract
  • Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract
  • Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract
• Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53)
  • Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025;Abstract 1019.
  • Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024;Abstract 104.
  • Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract
  • Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024;Abstract LBA1004.

CME information and select publications

Featuring perspectives from Prof Susana Banerjee and Dr Ursula Matulonis, including the following topics:

• Introduction: Tale of Two Cities — ASCO 2025 (0:00)
• Ovarian Cancer (11:20)
• HER2-Positive Gynecologic Cancers (31:28)
• Endometrial Cancer (40:16)
• Cervical Cancer (51:14)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 1: Ovarian Cancer — Ursula Matulonis, MD

CME information and select publications

Featuring an interview with Ms Kathleen D Burns, including the following topics:

• Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who received an androgen receptor inhibitor in combination with androgen deprivation therapy (0:00)
• Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) who received olaparib in combination with abiraterone (23:20)
• Case: A man in his mid 70s with mCRPC who received lutetium Lu 177 vipivotide tetraxetan (33:44)

NCPD information and select publications

Featuring an interview with Dr Hope S Rugo, including the following topics:

• Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00)
• Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03)
• Management of common toxicities with approved ADCs (10:48)
• Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17)
• Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics:

• Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00)
• Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49)
• Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44)
• Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29)
• Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19)

CME information and select publications